The abstract is read at the publisher; the summary is JClub's.
Genetic removal of CD22 in APPPS1 transgenic mice reduces amyloid-β pathology and protects parvalbumin-positive interneurons in an age-dependent manner.
- Why it matters: CD22 is present on brain myeloid cells in Alzheimer’s disease and is linked to inhibitory control of microglial phagocytosis, but its functional role in disease models is unclear.
- What they did: The study used APPPS1 mice with CD22 ablation and tested microglia and differentiated THP-1 cells for CLEC7A-driven activation and phagocytosis, measuring SYK signaling; it also applied epratuzumab to activate CD22.
- The result: CD22 loss enhanced CLEC7A-mediated activation and phagocytosis via increased SYK signaling, while CD22 activation with epratuzumab suppressed THP-1 activation, defining a CLEC7A–CD22–SYK inhibitory axis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.